Summary
Definition
History and exam
Key diagnostic factors
- presença de fatores de risco
- hematúria (visível ou não visível)
Other diagnostic factors
- polaciúria
- disúria
Risk factors
- exposição ao tabaco
- exposição a carcinógenos químicos
- idade >65 anos
- radiação pélvica
- uso de ciclofosfamida
- Infecção por Schistosoma
- sexo masculino
- inflamação crônica da bexiga
- predisposição genética
- diabetes mellitus
Diagnostic tests
1st tests to order
- urinálise
Tests to consider
- cistoscopia
- citologia da urina
- urograma por tomografia computadorizada (TC)
- urograma por ressonância magnética (RM)
- ultrassonografia renal e vesical
- Hemograma completo
- perfil bioquímico (incluindo fosfatase alcalina)
- radiografia torácica
- TC abdominal e de pelve
- ressonância nuclear magnética (RNM) abdominal e pélvica
- PET-TC com fluordesoxiglucose (FDG)
- cintilografia óssea
- biomarcadores urinários
Treatment algorithm
tumores não invasivos do músculo
tumores localmente invasivos
doença metastática
Contributors
Authors
Joshua J. Meeks, MD, PhD
Associate Professor of Urology
Northwestern University Feinberg School of Medicine
Chicago
IL
გაფრთხილება:
JJM is a consultant for Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, and Seagen/Astellas. He has received research funding from the VHA, NIH, and DoD; compensation for talks/educational courses from the AUA, OncLive, Olympus, and UroToday; and clinical trial support from SWOG, Genentech, Merck, AstraZeneca, and Incyte. JJM holds patents on T1 and TCGA classifiers; these are not currently available for use in clinical practice. JJM is an author of a reference cited in this topic.
David VanderWeele, MD, PhD
Associate Professor, Hematology and Oncology
Northwestern University Feinberg School of Medicine
Chicago
IL
გაფრთხილება:
DVW declares that he has received payments from Clovis Oncology, Exelixis, Janssen, and Bayer for advisory boards; research payments from AstraZeneca for clinical trials; payments from Astellas and Myovant for lectures; and payments from Exelixis and AstraZeneca for travel and dinner costs.
Sarah E. Fenton, MD, PhD
Assistant Professor, Hematology and Oncology
Northwestern University Feinberg School of Medicine
Chicago
IL
გაფრთხილება:
SEF declares that she has no competing interests.
მადლიერება
Dr Joshua J. Meeks, Dr David VanderWeele, and Dr Sarah E. Fenton would like to gratefully acknowledge Dr Donald Lamm and Dr Mary Heeley, previous contributors to this topic.
გაფრთხილება:
DL is an author of a number of references cited in this topic. MH declares that she has no competing interests.
რეცენზენტები
Junaid Masood, MBBS, FRCS (Eng), MSc (Urol), FRCS (Urol)
Consultant Urological Surgeon
Homerton University Hospital NHS Foundation Trust
London
UK
გაფრთხილება:
JM declares that he has no competing interests.
Hugh Mostafid, MD
Consultant Urologist
North Hampshire Hospital
Basingstoke
UK
გაფრთხილება:
HM has received honoraria from GE Healthcare and Kyowa Kirin UK.
Thomas Guzzo, MD
Clinical Instructor of Urology
The James Buchanan Brady Urologic Institute
The Johns Hopkins Medical Institutions
Baltimore
MD
გაფრთხილება:
TG declares that he has no competing interests.
Amir Kaisary, MD, MA, ChM, FRCS
Consultant Urological Surgeon
Honorary Senior Lecturer
Department of Urology
The Royal Free & University College Medical School
London
UK
გაფრთხილება:
AK declares that he has no competing interests.
წყაროები
ძირითადი სტატიები
American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO joint guideline. 2024 [internet publication].სრული ტექსტი
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer [internet publication].სრული ტექსტი
European Association of Urology. Non-muscle-invasive bladder cancer. 2023 [internet publication].სრული ტექსტი
European Association of Urology. Muscle-invasive and metastatic bladder cancer. 2024 [internet publication].სრული ტექსტი
American Urological Association. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. Apr 2024 [internet publication].სრული ტექსტი
გამოყენებული სტატიები
ამ თემაში მოხსენიებული წყაროების სრული სია ხელმისაწვდომია მომხმარებლებისთვის, რომლებსაც აქვთ წვდომა BMJ Best Practice-ის ყველა ნაწილზე.
დიფერენციული დიაგნოზები
- Hiperplasia prostática benigna (HPB)
- Cistite hemorrágica
- Prostatite
მეტი დიფერენციული დიაგნოზებიგაიდლაინები
- Suspected cancer: recognition and referral
- Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline
მეტი გაიდლაინებიპაციენტის ბროშურები
Câncer de bexiga
Больше Лифлеты для пациентаВойдите в учетную запись или оформите подписку, чтобы получить полноценный доступ к BMJ Best Practice
Использование этого контента попадает под действие нашего заявления об отказе от ответственности